2023年7月17日

試驗評估的影響anti-tau產品HMTM神經絲輕鏈。口服hydromethylthionine甲磺酸是用於治療阿爾茨海默氏症患者。TauRx製藥已報告的數據指定的三期清醒試驗分析口腔hydromethylthionine甲磺酸(HMTM)阿爾茨海默病(AD)患者。HMTM旨在減少τ病理學在廣告。推薦報告清醒組成12個月的雙盲對照試驗旨在研究各種臨床和生物標誌物的變化結果,緊隨其後的是12個月的時期。審判相比對氯化methylthioninium HMTM 16毫克/天(MTC) 4毫克每周服用兩次在頭12個月。神經絲輕鏈(NfL)是主要研究血液生物標誌物端點。試驗還評估anti-tau產品HMTM NfL的影響。橄欖球是一個確立了大腦神經退化的生物標誌物。HMTM 16毫克/天的劑量,NfL的顯著減少93%的血液水平的參與者在治療12個月觀察對照組。 This reduction was correlated significantly with a tau biomarker (p-tau 181) in blood. TauRx Pharmaceuticals executive chairman Claude Wischik said: “The NfL results demonstrate that a drug targeting tau pathology reduces the neurodegeneration that underlies the clinical decline in AD. “They bring us a step closer to offering an effective new treatment option for people with AD. “Because it is taken as a tablet and has a strong safety profile, HMTM would be readily accessible to people needing a disease-modifying treatment.” TauRx is planning to seek regulatory approval in the US, the UK and other territories based on the submission of results from LUCIDITY and earlier trials. It is also preparing to report both the NfL and the full 24-month data. HMTM is claimed to have a key advantage over other disease-modifying therapies (DMTs) , as it does not cause amyloid-related imaging abnormalities (ARIAs). Share this article